Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by Alba1314on Aug 22, 2018 8:12am
179 Views
Post# 28497604

RE:My Opinion

RE:My Opinion
Gamestorm7 wrote: If you look at the timeline of information and try and connect the dots, the story is being told before our eyes. Mr. Rae buys over 1M shares in May when (I'm assuming) the first results of Phase 1 clinical trials of Oral Amp B prove positive and show no toxicity.


That's insider trading. They're not allowed to buy and sell stock before the info is made public. I'm sure some CEOs leak info to friends//family/business partners,but a smart CEO wouldnt be so obvious about it when it came to their own shares. Overall though I liked the post. Appreciate the effort put into it.

I think it was MikPiks?? that was asking what would be viewed as bad news? Have to look at that 25M proscpectus and how much per share that capital is raised. No company out there will buy those shares at current market value which means dilution of current share value. I think they'll get issued at less than $0.10/share. There's a real potential for some serious dilution here. It's necessary,unavoidable, and part of the whole process. But will still be painful to those currently holding. If the the drug goes to market, it wont matter. You'll still make $$$. Right now I think it could either way with the financing and unless you have insider knowledge, it comes down to your best guess =)

<< Previous
Bullboard Posts
Next >>